Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models
- 5 April 2017
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (384)
- https://doi.org/10.1126/scitranslmed.aaf4696
Abstract
Pulmonary fibrosis is scarring of the lungs that can arise from radiation injury, drug toxicity, environmental or genetic causes, and for unknown reasons [idiopathic pulmonary fibrosis (IPF)]. Overexpression of collagen is a hallmark of organ fibrosis. We describe a peptide-based positron emission tomography (PET) probe (68Ga-CBP8) that targets collagen type I. We evaluated 68Ga-CBP8 in vivo in the bleomycin-induced mouse model of pulmonary fibrosis. 68Ga-CBP8 showed high specificity for pulmonary fibrosis and high target/background ratios in diseased animals. The lung PET signal and lung 68Ga-CBP8 uptake (quantified ex vivo) correlated linearly (r2 = 0.80) with the amount of lung collagen in mice with fibrosis. We further demonstrated that the 68Ga-CBP8 probe could be used to monitor response to treatment in a second mouse model of pulmonary fibrosis associated with vascular leak. Ex vivo analysis of lung tissue from patients with IPF supported the animal findings. These studies indicate that 68Ga-CBP8 is a promising candidate for noninvasive imaging of human pulmonary fibrosis.Keywords
Funding Information
- U.S. Department of Energy (award296945)
- National Heart, Lung, and Blood Institute (award296946)
- NIH Office of the Director (award296947)
- National Center for Research Resources (award296948)
This publication has 50 references indexed in Scilit:
- Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseNature Medicine, 2012
- Endoplasmic reticulum stress enhances fibrotic remodeling in the lungsProceedings of the National Academy of Sciences of the United States of America, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Prolonged Exposure to Sphingosine 1–Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung InjuryAmerican Journal of Respiratory Cell and Molecular Biology, 2010
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?The International Journal of Biochemistry & Cell Biology, 2008
- Inhibition of Integrin αvβ6, an Activator of Latent Transforming Growth Factor-β, Prevents Radiation-induced Lung FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- [18F]MK-9470, a positron emission tomography (PET) tracer forin vivohuman PET brain imaging of the cannabinoid-1 receptorProceedings of the National Academy of Sciences of the United States of America, 2007
- Idiopathic Pulmonary Fibrosis: Spectrum of High-Resolution CT FindingsAmerican Journal of Roentgenology, 2005